Dysfunctional Uterine Bleeding in Pediatrics Medication
- Author: Germaine L Defendi, MD, MS, FAAP; Chief Editor: Andrea L Zuckerman, MD more...
Pharmacotherapy is aimed at preventing medical complications of dysfunctional uterine bleeding (DUB) and includes the following:
Hormone therapy (eg, estrogen, combination estrogen-progestin) 
Therapies such as gonadotropin-releasing hormone (GnRH) agonists and selective estrogen receptor modulators (SERMs) have a limited place in the treatment of unresponsive bleeding; however, further medical investigation is warranted to support their routine use.
Anovulatory bleeding occurs as the hyperproliferative endometrium, lacking a progesterone effect, outgrows its estrogen supply, leading to irregular sloughing. Rapid return of adequate estrogen levels is the quickest way to decrease bleeding. Estrogens alone are primarily used for acute dysfunctional uterine bleeding when rapid control of the bleeding is required.
Administered PO, IM, or IV. Studies have demonstrated that similar blood levels are achieved at the same rate by any route. Parenteral therapy is reserved for patients who are unable to tolerate PO intake. Equivalent doses of other forms of estrogen (eg, estradiol, esterified estrogens, ethinyl estradiol, estropipate) are likely to be equally effective although clinical studies are lacking. Only the conjugated estrogens are approved by the FDA for this indication.
Individually, progestins are used to stabilize an estrogen-primed endometrium and are administered in a cyclic fashion. Because the pathophysiology of dysfunctional uterine bleeding is based on a relative estrogen deficiency, progestins alone should not be the first-line treatment for acute bleeding. Progestins should be administered along with estrogens, and this combination is discussed under oral contraceptive pills.
Continuous use of high-dose progestins, orally or in a depo-form, can induce endometrial atrophy and amenorrhea. This approach is useful for preventing future blood loss while correcting a significant anemia or when combination contraceptive pills do not achieve adequate control of bleeding.
May be administered PO, in a cyclic or continuous fashion, or as a parenteral depot formulation. When managing acute and heavy uterine bleeding, should be administered concurrently with an estrogen preparation. Progestins alone do not address the underlying pathophysiology of a hyperproliferative endometrium that has outgrown its estrogen supply.
Administered PO in a cyclic or continuous fashion. When managing acute and heavy uterine bleeding, should be administered concurrently with estrogen. Progestins alone do not address the underlying pathophysiology of a hyperproliferative endometrium that has outgrown its estrogen supply.
Oral contraceptive agents
Oral contraceptive agents or oral contraceptive pills (OCPs) provide a convenient method of rapidly delivering high-dose combinations of estrogen and progestin. The monophasic preparations offer the best opportunity for creating a stable endocrine environment. Most of the modern products contain 20, 30, or 35 mcg of ethinyl estradiol in combination with norethindrone or one of the second- or third-generation progestins. For all practical purposes, they are essentially equivalent.
This is one example of an OCP preparation. When treating light-flow irregular bleeding, OCPs are administered in the usual contraceptive fashion (ie, 1 tab PO qd for 21 d of a typical 28-d cycle). Treatment of acute heavy uterine bleeding, multiple tab are administered PO each day and then tapered once the heavy flow has ceased. If significant anemia is present, the placebo phase (ie, days 22-28) may be omitted for several mo.
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Studies have demonstrated a prostaglandin imbalance in women with menorrhagia and a reduction in menstrual flow with administration of NSAIDs. Several drugs in this category should have similar efficacy.
A classic example of this category of medications. For best efficacy, start the NSAID prior to the onset of flow. Have analgesic, anti-inflammatory, and antipyretic activities. Mechanism of action is nonselective inhibition of cyclooxygenases 1 and 2, resulting in reduced synthesis of prostaglandins and thromboxanes.
These agents inhibit fibrinolysis via inhibition of plasminogen activator substances, to a lesser degree, through antiplasmin activity.
Used for acute heavy uterine bleeding in patients with increased fibrinolytic activity. Discontinued once bleeding has stopped.
These are used to replenish iron stores lost during acute or chronic hemorrhage. The body stores iron in compounds called ferritin and hemosiderin for future use in the production of hemoglobin. Iron absorption is a variable of the existing body iron stores, the form and quantity in foods, and the combination of foods in the diet. The ferrous form of inorganic iron is more readily absorbed.
This is the most common medication for iron therapy though several other formulations are available.
Bravender T, Emans SJ. Menstrual disorders. Dysfunctional uterine bleeding. Pediatr Clin North Am. 1999 Jun. 46(3):545-53, viii. [Medline].
Coupey SM, Ahlstrom P. Common menstrual disorders. Pediatr Clin North Am. 1989 Jun. 36(3):551-71. [Medline].
Behera MA, Price TM. Dysfunctional uterine bleeding. Medscape Drugs & Diseases. September 29, 2014. [Full Text].
Lavin C. Dysfunctional uterine bleeding in adolescents. Curr Opin Pediatr. 1996 Aug. 8(4):328-32. [Medline].
Minjarez DA, Bradshaw KD. Abnormal uterine bleeding in adolescents. Obstet Gynecol Clin North Am. 2000 Mar. 27(1):63-78. [Medline].
Strickland J, Gibson EJ, Levine SB. Dysfunctional uterine bleeding in adolescents. J Pediatr Adolesc Gynecol. 2006 Feb. 19(1):49-51. [Medline].
Estephan A, Sinert RH. Dysfunctional uterine bleeding in emergency medicine. Medscape Drugs & Diseases. October 31, 2014. [Full Text].
Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011 Apr. 113(1):3-13. [Medline].
Collins J, Crosignani PG. Endometrial bleeding. Hum Reprod Update. 2007 Sep-Oct. 13(5):421-31. [Medline].
Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006 Nov. 118(5):2245-50. [Medline].
INDOX. Risk Factors for Breast Cancer in India: an INDOX Case-Control Study. INDOX Cancer Research Network. Available at http://indox.org.uk/node/34. Accessed: March 7, 2013.
Anderson SE, Must A. Interpreting the continued decline in the average age at menarche: results from two nationally representative surveys of U.S. girls studied 10 years apart. J Pediatr. 2005 Dec. 147(6):753-60. [Medline].
Al-Sahab B, Ardern CI, Hamadeh MJ, Tamim H. Age at menarche in Canada: results from the National Longitudinal Survey of Children & Youth. BMC Public Health. 2010 Nov 28. 10:736. [Medline]. [Full Text].
Hamilton-Fairley D. Lecture Notes. Obstetrics and Gynaecology. 2nd ed. Oxford, United Kingdom: Blackwell; 2004. [Full Text].
Mikhail S, Kouides P. von Willebrand disease in the pediatric and adolescent population. J Pediatr Adolesc Gynecol. 2010 Dec. 23(6 Suppl):S3-10. [Medline].
James AH. Women and bleeding disorders. Haemophilia. 2010 Jul. 16 Suppl 5:160-7. [Medline].
Austin SB, Ziyadeh NJ, Vohra S, et al. Irregular menses linked to vomiting in a nonclinical sample: findings from the National Eating Disorders Screening Program in high schools. J Adolesc Health. 2008 May. 42(5):450-7. [Medline]. [Full Text].
Meirow D, Rabinovici J, Katz D, Or R, Shufaro Y, Ben-Yehuda D. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer. 2006 Oct 1. 107(7):1634-41. [Medline].
Toth M, Patton DL, Esquenazi B, Shevchuk M, Thaler H, Divon M. Association between Chlamydia trachomatis and abnormal uterine bleeding. Am J Reprod Immunol. 2007 May. 57(5):361-6. [Medline].
Lee DY, Oh YK, Yoon BK, Choi D. Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems. Am J Obstet Gynecol. 2012 Mar. 206(3):213.e1-5. [Medline].
National Heart Lung and Blood Institute (NHLBI). The Diagnosis, Evaluation and Management of von Willebrand Disease -- 2008 Clinical Practice Guidelines. National Institutes of Health. 2008 February. [Full Text].
[Guideline] Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013 Jul. 122(1):176-85. [Medline].
Casablanca Y. Management of dysfunctional uterine bleeding. Obstet Gynecol Clin North Am. 2008 Jun. 35(2):219-34, viii. [Medline].
Stabinsky SA, Einstein M, Breen JL. Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding. Obstet Gynecol Surv. 1999 Jan. 54(1):61-72. [Medline].
Kadir RA, Edlund M, Von Mackensen S. The impact of menstrual disorders on quality of life in women with inherited bleeding disorders. Haemophilia. 2010 Sep 1. 16(5):832-9. [Medline].
Rajput R, Dhuan J, Agarwal S, Gahlaut PS. Central venous sinus thrombosis in a young woman taking norethindrone acetate for dysfunctional uterine bleeding: case report and review of literature. J Obstet Gynaecol Can. 2008 Aug. 30(8):680-3. [Medline].
Gultekin M, Diribas K, Buru E, Gokceoglu MA. Role of a non-hormonal oral anti-fibrinolytic hemostatic agent (tranexamic acid) for management of patients with dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 2009. 36(3):163-5. [Medline].